Humacyte, Inc.

The momentum for this stock is not very good. Humacyte, Inc. is not a good value stock. Humacyte, Inc. is not a good growth stock. Humacyte, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Humacyte, Inc..

News

Humacyte (NASDAQ:HUMA) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I

Zolmax EF Hutton Acquisition Co. I upgraded shares of Humacyte (NASDAQ:HUMA - Free Report) to a strong-buy rating in a report published on Monday, Zacks.com reports.\nA number of other analysts also recently...\n more…

Humacyte (NASDAQ:HUMA) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I

Ticker Report EF Hutton Acquisition Co. I upgraded shares of Humacyte (NASDAQ:HUMA - Free Report) to a strong-buy rating in a report published on Monday, Zacks.com reports. HUMA has been the topic of several other...\n more…

Humacyte initiated with bullish view at EF Hutton, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Benchmark Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)

Zolmax Humacyte (NASDAQ:HUMA - Get Free Report)s stock had its "buy" rating reissued by stock analysts at Benchmark in a note issued to investors on Thursday, Benzinga reports. They currently have a...\n more…

nVerses Capital LLC Takes $28,000 Position in Humacyte, Inc. (NASDAQ:HUMA)

Ticker Report nVerses Capital LLC purchased a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased...\n more…

Humacyte to Participate at Upcoming Investor Conferences in September

Globe Newswire DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...\n more…